Why and when to implement incretin therapy
Freeman, J.S.; Unger, J.
Journal of Family Practice 57(9 Suppl): S19-S25
2008
ISSN/ISBN: 1533-7294 PMID: 18786340 Document Number: 619401
Document emailed within 1 workday
Related Documents
Scheen, A.J.; Radermecker, R.P.; Philips, J.C.; Paquot, N. 2007: Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes Revue Medicale Suisse 3(122): 1884; 1886-1888Harada, N.; Inagaki, N. 2010: Incretin and incretin-based therapies Nihon Rinsho. Japanese Journal of Clinical Medicine 68(5): 931-942
Brunton, S.A. 2013: Integrating incretin-based therapy into type 2 diabetes management Journal of Family Practice 62(6 Suppl Cme): S1-S8
Unger, J.; Nadeau, D.A. 2007: Defining the role of incretin mimetic therapy in the management of type 2 diabetes Journal of Family Practice 56(12 Suppl New): S4
Rodbard, H.W. 2013: Increased priority for regimens involving incretin-based and insulin therapy Journal of Family Practice 62(12 Suppl Cme): S5-11
Campbell, R.K.; Cobble, M.E.; Reid, T.S.; Shomali, M.E. 2010: Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies Journal of Family Practice 59(9 Suppl 1: S20-S27
Fox, T.C.; Robinson, C.L. 1990: Establishing procedures to implement drug therapy rules Provider 16(10): 65-66
Hada, Y.; Yamauchi, T.; Kadowaki, T. 2010: Incretin related drugs Nihon Rinsho. Japanese Journal of Clinical Medicine 68(10): 1900-1905
Shibasaki, T.; Seino, S. 2011: Regulatory mechanism of incretin secretion Nihon Rinsho. Japanese Journal of Clinical Medicine 69(5): 803-807
Unger, J. 2010: Choosing among the incretin agents and why it matters Journal of Family Practice 59(5 Suppl): S30-S35
Dhungat, J.P. 2017: Gila Monster Lizard and Incretin-mimetics Journal of the Association of Physicians of India 65(4): 96
Whitehill, D. 2007: Treatment of type 2 diabetes mellitus and the incretin system South Dakota Medicine: the Journal of the South Dakota State Medical Association 60(5): 197; 199
Fujita, Y.; Haneda, M. 2011: Molecular mechanism of insulin secretion facilitated by incretin Nihon Rinsho. Japanese Journal of Clinical Medicine 69(5): 808-812
Vilsbøll, T.; Knop, F.K. 2007: Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus Ugeskrift for Laeger 169(22): 2101-2105
Katsuno, T.; Miyagawa, J.-I. 2012: Therapeutic indications of incretin-related derivatives and other oral hypoglycemic agents Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl 3): 693-698
Mest, H.-J. 2006: Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement Current Opinion in Investigational Drugs 7(4): 338-343
Nicolucci, A.; Rossi, M.Chiara. 2008: Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes Acta Bio-Medica: Atenei Parmensis 79(3): 184-191
Wagner, M. 1990: UHC to implement Edi system Modern Healthcare 20(21): 41
Kohler, C.L.; Davies, S.L.; Bailey, W.C. 1995: How to implement an asthma education program Clinics in Chest Medicine 16(4): 557-565
Hoglund, D.H. 2005: Should your hospital implement wireless solutions? Biomedical Instrumentation and Technology Suppl: 30